Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006–2014)

BACKGROUND: Patients treated with (neo)adjuvant trastuzumab who relapse and receive trastuzumab for metastatic breast cancer (MBC) are a growing population with little outcome data given their exclusion from most clinical trials. We aim to estimate survival outcomes for this trastuzumab ‘pre-treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Daniels, Benjamin, Kiely, Belinda E, Houssami, Nehmat, Lord, Sarah J, Dobbins, Timothy, Lu, Christine Y, Ward, Robyn L, Pearson, Sallie-Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Epidemiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808025/
https://www.ncbi.nlm.nih.gov/pubmed/29136405
http://dx.doi.org/10.1038/bjc.2017.405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808025/
https://www.ncbi.nlm.nih.gov/pubmed/29136405
http://dx.doi.org/10.1038/bjc.2017.405

Ejemplares similares